Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Restructuring Costs: 2022-2024

Historic Restructuring Costs for Akebia Therapeutics (AKBA) over the last 2 years, with Mar 2024 value amounting to $58,000.

  • Akebia Therapeutics' Restructuring Costs fell 45.28% to $58,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $239,000, marking a year-over-year decrease of 98.51%. This contributed to the annual value of $58,000 for FY2024, which is 67.96% down from last year.
  • Per Akebia Therapeutics' latest filing, its Restructuring Costs stood at $58,000 for Q1 2024, which was down 65.68% from $169,000 recorded in Q3 2023.
  • Akebia Therapeutics' 5-year Restructuring Costs high stood at $14.5 million for Q2 2022, and its period low was -$94,000 during Q2 2023.
  • Over the past 3 years, Akebia Therapeutics' median Restructuring Costs value was $169,000 (recorded in 2023), while the average stood at $2.3 million.
  • Data for Akebia Therapeutics' Restructuring Costs shows a maximum YoY slumped of 100.65% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Akebia Therapeutics' Restructuring Costs stood at $1.2 million in 2022, then decreased by 6.11% to $169,000 in 2023, then tumbled by 45.28% to $58,000 in 2024.
  • Its last three reported values are $58,000 in Q1 2024, $169,000 for Q3 2023, and -$94,000 during Q2 2023.